Home/Pipeline/HemoMax

HemoMax

Surgical Hemostasis & Wound Closure

Pre-clinicalActive

Key Facts

Indication
Surgical Hemostasis & Wound Closure
Phase
Pre-clinical
Status
Active
Company

About Limax Biosciences

Limax Biosciences is a pioneering biomaterials company leveraging a nature-inspired hydrogel platform to create next-generation tissue adhesives. Founded in 2020 as a spinout from the Wyss Institute at Harvard University, the company is developing HemoMax, a tough, stretchable, and biocompatible adhesive aimed at revolutionizing surgical hemostasis, wound healing, and drug delivery. Positioned in the high-growth biologics and immunology sectors, Limax is targeting significant unmet needs in surgical and wound care with a product that claims performance superior to existing sealants and sutures.

View full company profile